As a dermatology resident in Daegu, I am increasingly disturbed by the clinical implementation of 'skin boosters' derived from processed human cadaveric tissue. Recently, I have seen a surge in patients inquiring about products like Elravie Re20, which utilizes acellular dermal matrix technology sourced—quite controversially—from American donors.

While the regenerative potential of human-derived collagen is scientifically fascinating, the current lack of rigorous longitudinal safety data is unacceptable. My colleagues and I have discussed the inherent risks of pathogen transmission; despite claims of sterility, the possibility of latent viral or prionic contamination in human tissue remains a non-zero risk that many aesthetic clinics downplay for profit.

Furthermore, the recent raids in Hong Kong seizing unregistered vials underscore a massive regulatory failure. We are MDs, not cosmetic salesmen. Injecting biological material into the dermis requires absolute clinical certainty, not just marketing hype about 'cadaver skin.' As a professional, I believe we must prioritize strict biosafety protocols and ethical sourcing over the 'quick-fix' demands of the K-beauty market. If we don't demand better oversight, we risk compromising the integrity of Korean aesthetic medicine.